Change theme to redChange theme to blueChange theme to greenChoose your color
 

Technologies Available for Licensing

For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@mail.mil



COMPOSITIONS FOR TREATMENT OF HEMORRHAGING WITH ACTIVATED FACOR VIIA IN COMBINATION WITH FIBRINOGEN AND METHODS OF USING SAME

The combination of recombinant factor VIIa and fibrinogen is effective in treatment for bleeding where direct pressure, tourniquets, indirect pressure, surgical ligation, bandaging, and transfusion of blood or plasma products are typically used. The combination of factor VIIa and fibrinogen is administered intravenously, either sequentially or simultaneously. The compositions may be safely circulated in the blood vessels to sites of injury. This is effective for single or multiple external or internal wounds.


Docket:WRAIR 2000-02

Publication/Issued No.:6,825,323

Publication/Issue Date:2004-11-30

Categories: Treatment

More Detail:Visit USPTO.GOVExternal link

Lab:WRAIR

Inventor(s):HESS, J.


For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@mail.mil
 

iSalute

This Web site provides an introduction to the Office of Research and Technology Applications (ORTA) and contains official Government information.

Its use is intended for members of the general public, news media and Military Health System beneficiaries.

Please address questions or concerns about this Web site to the USAMRMC Public Affairs Office at:
usarmy.detrick.medcom-usamrmc.list.webmaster@mail.mil or by telephone at (301)619-2736